ClinTec International, a global CRO with a substantial presence in the Middle East and Africa has expanded its operations into Malawi, appointing its first highly experienced clinical research associates. A top five pharmaceutical company with sales exceeding $50 billion has selected ClinTec as its preferred partner for vaccine development in Africa and Asia, further enhancing ClinTec’s growing presence in the emerging markets of Africa, Asia and the Middle East.
Africa is a pivotal region for the development of adult and paediatric vaccines against infectious diseases and ClinTec is well placed to participate in these programmes. The company is in the process of recruiting highly skilled personnel with vaccine research experience to join its already established teams in Africa and Asia, in preparation for strong growth ahead from these geographic markets.
Vaccine development faces its own challenges associated with local immunisation recommendations as well as stringent cold chain management. ClinTec’s team has the experience and understanding of the local challenges involved in working effectively in Africa and Asia, whilst complying in full with international clinical research guidelines.
ClinTec, winner of the 2011 Queen’s Award for Enterprise, operates in over 40 countries to provide specialist clinical research personnel and support services to its clients, which includes 11 of the top 25 pharma companies. ClinTec has grown organically since its inception in the UK in 1997, and has recently reported a 429 per cent growth rate over the five-year period from 2006 to 2011. It was one of the first CROs to establish a presence in the Middle East and Africa and has continued to strengthen its presence in the emerging markets as well as the more traditional Western European clinical research marketplace.
Commenting on the opening of ClinTec’s Malawi operations, Dr Rabinder Buttar stated, “I am pleased with our continued expansion in Africa and see a huge potential for the company in conducting large scale vaccine trials. Despite the challenging economic conditions through which many of our clients are restructuring their organisations, ClinTec continues to grow and win major new business from pharma companies.
The company is continuing to expand into interesting new regions for clinical research. As the pharma industry increasingly focuses its drug development efforts on the emerging markets, ClinTec will closely partner with its clients, aligning its services and operations to fit with their needs.”
EP News Bureau
- Advertisement -
